Evaluation of REGN6569 and Cemiplimab in Adults with Advanced Squamous Cell Carcinoma of the Head and Neck

The primary objective of this study is to evaluate the efficacy and safety of **REGN6569** in combination with **Cemiplimab** in adult patients diagnosed with advanced **Squamous Cell Carcinoma of Head and Neck**. This investigation is clinically relevant as it aims to explore potential therapeutic options for a malignancy that often presents with limited treatment alternatives and poor prognosis. The study seeks to determine the impact of this combination therapy on tumor response and patient outcomes, contributing to the advancement of treatment strategies for this aggressive cancer type.

The clinical trial involves a total of **66 participants** diagnosed with **Squamous Cell Carcinoma of Head and Neck**. The study population includes both male and female subjects, with an age range corresponding to categories 3 and 4, which typically represent adults and older adults. Participants were selected to include a vulnerable population, although specific inclusion or exclusion criteria were not provided. The general health status of the participants is not detailed, nor are any lifestyle considerations such as diet, physical activity, or habits. The sponsor has not disclosed further information regarding the selection process or additional demographic details.

The clinical trial is designed to evaluate the safety and efficacy of **REGN6569** and **Cemiplimab** in adult patients diagnosed with **Squamous Cell Carcinoma of Head and Neck**. This study is structured as a Phase 1 trial, employing a randomized, double-blind, and controlled methodology to ensure the reliability and validity of the results. The trial commenced on January 4, 2021, and is projected to conclude by June 22, 2026, encompassing a comprehensive duration to adequately assess the investigational treatments.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit, where eligibility criteria are assessed. This initial visit is crucial for determining participant suitability based on predefined inclusion and exclusion criteria. Following successful screening, participants will be randomized into treatment groups and will attend regular follow-up visits. These visits are scheduled to monitor the participants' health, assess treatment efficacy, and document any adverse events. The end-of-study visit marks the final assessment, where comprehensive data collection is completed, and participants are evaluated for any long-term effects of the treatment.

The expected length of participant involvement in the trial is contingent upon individual response to treatment and overall health status, with provisions for early termination if necessary. Conditions that may lead to early withdrawal include significant adverse reactions, disease progression, or withdrawal of consent by the participant. The trial is conducted under strict ethical guidelines, ensuring participant safety and data integrity throughout the study duration.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In this clinical trial, there is no mention of any **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatment being used. The data does not provide details on any additional relevant information about drug administration, dosing schedules, or participant compliance monitoring. Consequently, the trial documentation lacks comprehensive information on the treatment protocols and participant management strategies.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, which typically focuses on assessing safety, tolerability, and pharmacokinetics, but may also include preliminary efficacy assessments. The trial is scheduled to commence recruitment on January 4, 2021, with an estimated completion date of June 22, 2026. Although specific efficacy endpoints are not detailed, Phase 1 trials often utilize various parameters such as **biomarker** levels or symptom improvement scores to evaluate potential therapeutic effects. The methods and schedule for measuring, collecting, and analyzing these parameters are not specified, but they generally involve validated scales, laboratory tests, or patient-reported outcomes at predetermined timepoints. The trial's design and execution will adhere to rigorous scientific standards to ensure the reliability and validity of the efficacy assessments.